The landscape of metabolic health shifted significantly as the US FDA granted Breakthrough Therapy Designation to efimosfermin, a once-monthly investigational liver therapy targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH) (My, 2026).
Concurrently, the European Medicines Agency awarded the drug PRIME status (My, 2026). Phase II data revealed that the subcutaneous injection significantly reduces liver fat, ameliorates inflammation, and successfully reverses liver fibrosis (My, 2026).
With MASH serving as a leading cause of liver transplants globally, this regulatory fast-track offers immense hope for millions lacking viable treatment options.
